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Abstract
In Vivo exit  dosimetry is an approach that  has been under investigation as a tool to narrow down 
the uncertainties associated to proton beam range of dosimetric distributions. The goal of the project is 
to investigate the feasibility of different dosimeters to minimize the currently established range 
uncertainty value of ±3%. Measuring the exit dose of certain fields with dosimeters placed in a head 
phantom surface and compare it  with the dose predicted by the treatment planning system (TPS) for 
the respective dosimetric plan, one can know whether the dose is being overestimated or 
underestimated. Two cases can happen: if it  is experimentally measured a certain amount  of dose, the 
current dosimetric plan calculated by the TPS is being underestimated. Consequently, undershooting 
scenarios on the phantom can be discarded. On the other hand, if no dose is measured with the 
dosimeters, overshooting scenarios can be discarded. Five different  dosimeters were tested in the head 
phantom in order to develop a feasible standard procedure for the external in vivo dosimetry (EIVD) 
approach. Two different  methods were performed: a first  method where TLDs and the ionization 
chamber (IC) Semiflex (125 mm3) (from PTW) were placed on the surface of the phantom in 4 
different  points; and a second method where the 2D array detector (from PTW) was placed 
perpendicular to the beam, behind the phantom on the opposite side of the gantry nozzle. TLDs, two 
ICs (Semiflex and Advanced Markus (PTW)) and a diamond detector were placed on the surface of 
the 2D array over 2 specific points. In the first  method two dosimetric plans were measured: a nominal 
scenario and a overshooting scenario (characterized by a change of +3% in the Hounsfield units (HU) 
CT), representing the maximum range error possible. Both were used with a clinical field of protons 
(110º gantry, 180º couch rotation). In the second method, along with the latter scenarios a 10% 
overshooting scenario was added (HU of the CT changed by +10%) and a experimental field was used 
(90º gantry, 180º couch rotation). After the necessary results post-processing, the comparison between 
the measurements obtained experimentally and the respective dose predicted by the TPS (PSIplan) 
was done. The results show that  the dose measured by the dosimeters is not  within the ±3% of 
uncertainty in the range used at  Paul Scherrer Intitut (PSI) due to errors inherent to the methods used. 
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Several approaches were made to overcome this methodological errors, without  relevant 
improvements, however. Therefore, was not found any feasible dosimeter for such EIVD approach.
ii
Resumo
A dosimetria de verificação in vivo é uma abordagem que tem sido objeto de estudo como um 
método para diminuir as incertezas associadas ao alcance de feixes de protões em planos dosimétricos. 
O objetivo do projeto é investigar a viabilidade da utilização de diferentes dosímetros para minimizar 
o valor da incerteza atualmente estabelecido de ±3%. Medindo a dose resultante de certos campos de 
protões que atravessam um fantoma (simulação de uma cabeça humana), com dosímetros colocados 
na sua superfície, e compará-la com a dose calculada pelo sistema de planeamento dosimétrico para o 
respectivo plano dosimétrico, é possível saber se a dose está a ser sobrestimada ou subestimada. Dois 
casos podem acontecer: se for medida experimentalmente uma certa quantidade de dose, o plano 
dosimétrico calculado pelo sistema de planeamento está subestimado. Consequentemente, cenários 
com uma distribuição de dose subestimada no fantoma podem ser descartados. Por outro lado, se 
nenhuma dose é medida com os dosímetros, cenários com a distribuição de dose sobrestimada podem 
ser colocados de lado. Cinco dosímetros com diferentes características foram testados no fantoma de 
forma a desenvolver um procedimento padrão viável para a dosimetria externa in vivo. Foram 
realizados dois métodos: no primeiro método TLDs e uma câmara de ionização (IC) (Semiflex (125 
mm3) da PTW) foram colocados na superfície do fantoma em 4 pontos diferentes. No segundo 
método, um detetor planar (“2D array” da PTW) foi colocado perpendicularmente ao feixe, atrás do 
fantoma, e os TLDs, duas câmaras de ionização (Semiflex e advanced Markus (PTW)) e um detetor de 
diamante (diamond detector) foram colocados sobre a superfície da 2D array em 2 pontos específicos. 
No primeiro método dois planos dosimétricos foram utilizados para as medições: um plano nominal e 
um plano sobrestimado em 3%, isto é, com as unidades de Hounsfield (HU) da tomografia 
computorizada (TAC) alteradas em +3%, representando o erro máximo possível no alcance. Ambos 
foram usadas com um campo clínico de protões (110º rotação da gantry, 180º rotação da mesa). No 
segundo método, juntamente com os últimos planos, um plano sobrestimado em 10% foi adicionado 
(HU da TAC alteradas em + 10%) e um campo experimental de protões foi utilizado (90º rotação da 
gantry, 180º rotação da mesa). Depois do processamento dos resultados necessário, foi efetuada a 
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comparação entre as medições obtidas experimentalmente e a dose respetiva prevista pelo sistema de 
planeamento (PSIplan). Os resultados mostram que a dose medida pelos dosímetros não está dentro da 
incerteza no alcance utilizada no Paul Scherrer instituto (PSI) devido a erros inerentes aos métodos 
utilizados. Várias abordagens foram feitas para contornar estes erros metodológicos, no entanto sem 
melhorias relevantes. Não foi portanto encontrado nenhum dosímetro viável para o método de 
dosimetria externa in vivo proposto.
iv
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1. Introduction
Nowadays, it  is a known reality that  cancer is among the main causes of death worldwide. In 
2012 it  was registered about 8.2 million of cancer deaths. Due to the advances of the medical 
knowledge and the high evolution of the intersection of technology with medicine in the past  decades, 
the death cases have been decreasing, however, it is expected a rise of the annual cancer cases from 14 
million, in 2012, to 22 million within the next two decades [1]. These numbers reflect  the importance 
of research and investment  in new medical techniques and essentially the reinforcement  of the well 
established technology.
Cancer can be generally treated by one or more selection of medical interventions such as: 
surgery, chemotherapy and radiotherapy. Each one of these medical modalities are vast and 
characterized by an extensive set  of techniques emerged from the intersection of the knowledge 
between different scientific fields. Unquestionably, radiotherapy owes its existence to this interchange, 
specifically to the evolution of technology driven by the Engineering and Physics fields. Therefore, 
radiotherapy is object of study within Biomedical Engineering including thus the relation with these 
transversal scientific areas. This thesis contemplates the study and research of a current  issue within 
proton therapy, which is one of the particle therapies that constitute the external radiotherapy field.
The main challenge as well as the goal of external radiotherapy is to deliver a certain prescribed 
amount of dose to the treatment  tumor volume by means of ionizing radiation, whilst sparing the 
surrounding healthy tissue as much as possible. Since the radiation source is located outside the 
patient, the radiation will always transverse the healthy tissue to reach the tumor and deposit  energy on 
it. Although the technical impossibility to completely spare it, one can obtain clinical acceptable 
treatment plans according the treatment  characteristics implemented such as: the ionizing radiation 
employed; the clinical case involved (for instance the localization of the tumor), the correspondent 
delivery treatment  technique (the position and number of fields for instance) and the inherent 
optimization technique (in conventional radiotherapy for instance, whether it is used IMPT or not). 
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External radiotherapy is performed with different kind of particles. The so called conventional 
radiotherapy uses photons and electrons and is by far the most worldwide available technique, since 
the costs involved to create the necessary technology are much lower. Additionally protons are also 
used and in a much lesser extent, heavy ions like carbon ions. They are called respectively, proton 
therapy and heavy-ion therapy.
Regarding the protons, their physical characteristics of interaction with matter have a big 
potential. Specifically, the integral dose along the path of the protons, when interacting with matter, 
shows a sharp peak (Bragg-peak) followed by a steep fall-off region. This steep dose gradient at the 
distal edge of the Bragg peak is consequently translated in a well-defined finite range. The exploitation 
of this physical property through the techniques available nowadays, result in a treatment  with a lower 
integral dose to the patient and a dose deposition highly localized in the target  when using proton 
therapy rather than conventional radiotherapy. Therefore, theoretically, there is a gain in the 
therapeutic ratio1. Maintaining the target prescribed dose, it  is also verified, roughly, a reduction of the 
total energy deposited when treating a tumor by a factor of three, when compared with conformal 
photon radiotherapy, and by a factor of two when compared with intensity modulated radiotherapy 
(IMRT) [2, 3].
However, these same physical characteristics also make the calculation of the exact range and 
localization of the beam an important  issue to be considered, otherwise they can likely induce a 
clinically unwanted impact  on the predicted treatment [2, 4]. In practice, an underestimation of the 
range might cause an over-dosage of healthy tissue, i.e. a clinical overshooting treatment, whereas an 
overestimation might  lead to an under-dosage of the whole tumor volume and to a clinical 
undershooting treatment.
These uncertainties of a proton beam come from multiple sources and they are the main factor 
which actually limit the fully exploitation of the proton therapy potential. In fact, if this issue is 
overcome or at least minimized, several clinical cases which are nowadays performed using photon 
therapy treatments could be improved significantly through proton therapy treatments. For instance, in 
prostate cancer treatments using radiation therapy, the finite range of proton beams could be used as a 
tool to create an anterior single field plan, shielding critical structures (such as the rectum) with shorter 
path lengths through healthy tissue. However, the standard treatments of prostate cancer employ 
proton parallel-opposed lateral beams or advanced forms of conventional radiotherapy (such as 
intensity-modulated radiotherapy (IMRT)), just  because this method is more robust to proton beam 
uncertainties, despite increasing the volume of healthy tissue irradiation [5]. 
These range uncertainties and the way to deal with them are indeed a relevant issue in proton 
therapy and has been an important topic of investigation within the research community. The later 
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1 The therapeutic ratio is defined as the ratio between the probabilities for tumor eradication and normal tissue complication
example shows the importance of being able to monitor the range of the proton beams in vivo. This 
thesis is focused then in trying to find a way of measuring the dose in vivo, out  of the patient, since it 
can be directly a relevant tool to evaluate and decrease the uncertainty in the range. In vivo dosimetry 
in external radiotherapy has already been a clinical solution to deal with this issue and, undoubtedly, 
an important research topic within proton therapy breakthroughs [6]. 
1.1. Paul Scherrer Institut - Center for Proton Therapy
This thesis is a result of a internship project  elaborated at Paul Scherrer Institut  (PSI), in 
Switzerland. PSI is actually the main research center for natural and engineering sciences within 
Switzerland. It focuses on the long-term research in three different areas: Matter and Material, Energy 
and Environment and Human Health. The Center for Proton Therapy (CPT) has been treating patients 
since 1984, when it was installed an horizontal beam line to treat  ocular melanomas. Since 1996 the 
first  proton therapy gantry developed in-house has been in operation and in November 2013 the new 
Gantry 2 began treating patients with more advanced techniques. Never ceasing to be a leader in 
research and development  (R&D), CPT  started in fact  treating patients as a year-round facility in 2007, 
when the new dedicated cyclotron for medical purposes was lunched. A new gantry (Gantry 3) is being 
under construction, with the same treatment  capabilities of Gantry 2, and is planned to be lunched in 
2016 [7].
1.2. Objectives
The finite range of protons is one of the major advantages which led to the development of 
proton therapy. The way to overcome its inherent uncertainty however, is actually one of the foremost 
research topics not only at PSI but  also in the world proton therapy community. This thesis is a result 
of an experimental project which was held in CPT  at  PSI, and follows the development pathway of 
robustness in treatment planning techniques that has been carrying out in CPT R&D program. It 
focuses on the feasibility of using point dosimeters to verify the range of the beam in order to narrow 
down as much as possible its uncertainties. 
The motivation of the project arises because it was verified in some exceptional cases, with a 
superficial target, that  the protons can go through the patient and deposit  a considerable amount of 
dose in a healthy tissue. In the example of a patient  plan approved for treatment displayed in the figure 
1, this is the case, where one can find doses between 20% and 90% of the prescribed dose in the 
healthy tissue located in the exit region of the beam, out of the target.
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Figure 1: Clinical plan treatment performed at PSI. It is clear that there are still dose between 20% and 90% of the dose prescribed in the 
healthy tissue located in exit region of the beam
The main aim of the project  is then measure with different point dosimeters the dose delivered 
by a proton beam on the surface of the skin, in the distal edge of the target. The experiments are 
performed on a head phantom existent  at CPT specifically made for proton therapy research 
experiments.  Two results can be obtained: either it  is measured some dose, meaning the range is being 
underestimated by the TPS and undershooting scenarios no longer are taken into account; or it  is not 
measured any dose and overshooting scenarios can be discarded. Therefore, the result  will always be 
automatically useful whether is measured dose or not. Depending on the relevance of the results 
obtained, setting up a standard procedure to test this external in vivo dosimetry approach (EIVD) is 
also a goal.
1.3. State of art
In conventional radiotherapy, in vivo dosimetry has been a simple and accurate safety tool to 
avoid dose delivery errors during specific treatments and a wide range of EIVD techniques have been 
developed [6]. Due to the high sensitivity of proton therapy delivery calculations to range errors these 
EIVD approaches are for sure an asset.
Regarding the direct  methods of in vivo range verification, Mumot et al (2010) proposed the 
concept of 'range probe', i.e. a proton pencil beam with low-dose but high-energy which penetrates 
through the patient  where a multi-detector would measure the integral Bragg peak dose. Such 
measurement  would be compared with the one calculated by the TPS so that  the accuracy of the range 
in vivo could be evaluated. Based on Monte Carlo simulations it appears feasible that range errors in 
the order of 1 millimeter could be detected [8]. This approach is simple, requiring only a commercial 
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multi-layer ionization chamber (MLIC) detector, however, it requires high energy protons (around 250 
MeV), depositing unnecessary dose at  the patient; shows a low resolution and is not able to measure 
the range directly at  the exit of the tumor position, only the range through the whole patient body [2]. 
In order to improve the range verification of point based dosimetry Lu et  al (2008) explore the 
properties of range modulated passive scattering fields, more precisely the fact that  at  any point of the 
target, the time dependence of a spread out Bragg peak (SOBP) distribution is unique. So measuring 
with a point  dosimeter this time dependence of the dose rate one is able to determine the depth 
information and then the residual range of the beam can be predicted with millimeter accuracy [9]. 
This approach is however limited to this delivery system (SOBP). Additionally, the dosimeters must 
be placed close or within the target volume, which is not  always possible and is invasive for the 
patient. Besides, these tests were performed in an homogeneous water phantom environment  and this 
approach remains to be validated either in heterogeneous body phantoms or in real clinical situations 
[2]. The accuracy of the implanted markers methods will be extremely dependent of the heterogeneity 
effects of the patient body structure but  indeed a real conclusion about  the accuracy remains to be 
investigated in those circumstances. 
Apart from point  dosimetry, 2D tools for in vivo dose measurements have been as well 
developed. Proton radiography is a technique which requires high energy protons applied to the patient 
[10]. Beyond the advantages of proton radiography against x-ray radiography, in this context, the use 
of this approach is justified by the fact that  it directly provides the tissue stopping power values. 
Therefore, the uncertainties would be minimized since the computer tomography (CT) Hounsfield 
units (HU) to stopping power calibration as well as it  inherent uncertainties would not be anymore 
presented within proton therapy technique [2]. Despite these clear advantages proton radiography has 
not progressed rapidly and clinical implementation is still a distant expectation.
Besides the latter approaches there are as well other methods able to verify the proton range in 
vivo in an indirect way. Along the proton path, inelastic interactions with the target nuclei occur, 
leading to its excitation to a higher energy state and consequently emitting a single photon (prompt 
gammas) to return to its ground state. The direct  employment  of this radiation for range verification 
was first proposed by Min et  al. They suggest  that  the correlation of high energy prompt gamma rays 
with the penetration path of protons in the tissue can be used to indirectly verify the proton range. 
Although the prompt gamma fall-off is not equal to the proton fall-off a consistent  and predictable fall-
off differences allow the proton range verification [11]. Currently the application has failed because 
has not  been developed so far a optimized prompt  gamma detector, however, considering recent 
developments, sub-millimeter precision in range measurements seem to be feasible [12]. Moreover, 
with this approach the range verification is able to be performed in real time and without additional 
dose [2].
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The use of positron emission tomography (PET) as a tool to verify the proton range was firstly 
investigated by several groups world wide in the 90's [13-16] but continues under development both 
for protons and heavier ions. The method is based on the detection of beta+ activity which is formed 
by inelastic collisions between protons and elements in tissue. Specifically, the inelastic nuclear 
reaction cross sections tend to occur at  higher energies along most of the beam flat  path and decrease 
at  the Bragg peak zone i.e there are a diminish of the positron emitters concentration [17]. Analyzing 
PET  image it shows beta+ activity up to the Bragg peak and then falls off. Therefore, comparing the 
measured distributions by PET with predictions based on the treatment  plan, it  is possible an effective 
range verification. This approach could be used both off-line, with a little delay after the treatment in a 
commercial PET scanner, or on-line, directly following the treatment with a facility specific detector 
solution. For the latter only 3 clinical installation exist  and several technical improvements are 
required. In general the accuracy of the range verification is around 5-10 mm [18]. 
Finally, in vivo dose verification using magnetic resonance imaging (MRI) has been reported in 
several studies among which the work of Gensheimer et  al stands out. One of the consequences of 
ionizing radiation is that it can cause alterations in the human tissue which are able to be detected by 
MRI [19]. This is hence a off-line method with high spatial resolution and no additional ionizing 
radiation. Nevertheless, a visual evaluation is not  sufficient to verify the proton range because the 
location of the greatest signal intensity (SI) does not correspond necessarily to the delivery dose 
gradient. The relation dose-SI is not  linear and is not well established but if such relation could be 
found, sub-millimeter precision is conceivable. The low temporal evolution of the MR signal (about  8 
days was reported) is still as well an disadvantage [2].
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2. Fundamental concepts
Proton therapy is an external radiotherapy modality which uses protons to delivery the required 
dose distribution for a given target  in a patient  in order to treat a patient with cancer. Between the 
proton acceleration until the end of beam delivery system, there are many and complex engineering 
techniques developed during the later decades integrated in this therapy method. Apart  from that, there 
are implicit in these techniques a vast amount  of physics concepts. Therefore this chapter contemplates 
the main concepts and techniques that  had a direct  relation with the development  of the project and 
enable the understanding of the results.
2.1. Physics
2.1.1. Protons interaction in matter
The most important interactions of particles with the matter are actually well defined by physics 
models. Each particle, depending on their fundamental characteristics such as size or charge, shows a 
different  way of interaction. The characteristics of the therapy performed is then closely related with 
the particle used. Specifically for the purpose of the project, understand how protons interact with 
tissue is fundamental.
2.1.1.1. Stopping power
When protons go through the matter they are subjected to electromagnetic Coulomb interactions 
with the orbiting electrons of atoms resulting in continuous loss of energy. These interactions lead to 
the ionization and excitation of atoms and set  free electrons that ionize other atoms in the 
neighborhood. Although the protons lose little energy and almost no deflection in these individual 
interactions, they experience thousands of interactions per centimeter [20]. The rate at  which they lose 
energy, transferring it  to the tissue, increases with the penetration depth and is described by the mass 
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stopping power. For protons, which have mass higher than electrons, the stopping power is described 
by the Bethe-Bloch equation [3]:
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in MeV·cm2/g as SI unit. Concerning the parameters relative to the medium, ρ is the density, Z and A 
are respectively the atomic and nuclear number and I the mean excitation energy. The latter one can 
not be calculated with relatively good accuracy so it  is inevitable a cause of uncertainty in the proton 
range. On the other hand Tmax is the maximum proton energy transferred to a free electron in a single 
collision and is given by:
Tmax =
2mec2! 2
1!! 2 ,
(2.2)
where me is the electron mass, c the velocity of the light  and β is a kinematic term equal to v/c. The 
examination of the Bethe-Bloch equation reveals the approximate proportionality: S(E)∝1/v2, for low 
energy protons [2, 3]. The smaller the velocity of the protons, the higher the energy loss.
2.1.1.2. Multiple Coulomb scattering
Protons are also scattered by the atomic nucleus, resulting in an angular deflection of their path. 
Despite they experience also a slightly deflection due to electrons of the atoms of the matter, this is 
almost irrelevant, since the protons are 1800 times heavier. Consequently this effect is ignored in some 
mathematical models without  relevant consequences [2]. On the other hand, when a proton passes 
close to an atom nuclei, which is heavier than an electron, suffers an repulsive electrostatic force 
resulted from the positive charge of the nucleus. This interaction leads to a small but relevant 
deflection in the proton path. Along its path the proton suffers  many small deflections which add up to 
a statistical significant  angular deviation. The resultant  scattering is named Multiple Coulomb 
scattering (MCS) [2, 20]. 
2.1.1.3. Nuclear interactions
Together with the Coulomb interactions with the electrons and nuclei, primary protons have a 
small probability of suffering elastic and nonelastic nuclear interactions. In elastic nuclear collisions, 
the proton is deflected by several degrees but the nuclei maintains intact and kinetic energy is 
conserved. On the other hand, and more important, in nonelastic collisions the nuclei may breakup, 
changing its initial characteristics, and secondary particles such as secondary protons, neutrons, γ rays, 
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heavy fragments (alpha particles) are emitted. After the interaction the primary proton is then widely 
deflected and loses a significant  part  of its initial energy. The secondary particles have in general much 
lower energy and larger scatter angles than the incident primary proton. Around 1% of protons per 
centimeter are lost from the beam due to nonelastic interactions [2, 3].  
These nonelastic interactions are difficult to model, either analytical or using Monte Carlo 
simulations, however, since their biological effect is considerable small they are taken into account in 
the beam design by using measured experimental Bragg peaks [3].
2.1.2. Fundamental physical quantities
In the radiation physics field, and in the context  of the project, there are some physical 
quantities that  must  be defined. The proton therapy treatments uses then the energy deposited by the 
proton beams to destroy the tumors. In radiotherapy, the quantity absorbed dose is the measurable 
standard for the amount of ionizing radiation in a medium, particularly a tissue, and it  is defined as the 
mean energy absorbed per unit mass:
D = dEdm .
(2.3)
The SI unit of dose used in radiotherapy is the Gray (Gy), which corresponds to J/kg  [3, 21, 22].
The damage of the radiation can be thus evaluated as a function of dose, i.e, there are a dose-
response relationship, however, this biological effect depend as well on the radiation. Protons, for 
instance, are more biologically effective than photons meaning that  is necessary lower dose when 
using protons to reach the same biological effect. To evaluate this effect the relative biological 
effectiveness (RBE) value, which uses the x-rays as reference, is defined: 
RBE = DxD ,
(2.4)
where D corresponds to the value of a certain radiation dose which lead to a specific biological effect 
while Dx is the x-ray dose necessary to produce the same effect [3, 21]. In order to maintain the 
consistency in the clinical and due to the large quantity of clinical results with photon beams available, 
the dose is prescribed as photon doses regardless of the type of radiation [3]. However, the dose can 
still be evaluated taking into account the RBE, simply dividing the photon dose by the RBE value. 
Regarding proton therapy, the value of RBE for protons is 1.1, a value calculated with animal 
experiments in the earlier days. Despite this parameter has a dependency on different physical and 
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biological parameters it  is used as a constant value. In fact  there are no clinical indication that 1.1 can 
lead to unexpected results and side effects and a generic value allow a straightforward conversion 
from photon doses into proton doses of clinical treatments [3].
2.1.3. Depth dose distribution - Bragg peak
The physical interactions referred above result  in a dose to the tissue along the protons path. 
This dose distribution of the protons in depth shows a peak, representing a large increasing of dose just 
before the protons stop, resulting from the increasing of the stopping power as the protons slow down. 
This depth dose curve is named Bragg peak and contrasts with the short  dose build-up followed by a 
exponential-like decay of the photons dose distribution (figure 2). This characteristic is the basis of 
proton therapy. In fact the techniques of proton therapy are essentially different ways to manipulate 
this Bragg peak in order to optimize the treatment: covering the target and sparing the healthy tissues 
as far as possible [3]. 
Figure 2: Representation of the depth dose curve (Bragg curve) and spread-out Bragg peak (SOBP) of protons compared to 
the depth dose curve of a 15 MV photon beam. The yellow area indicates the amount of dose that can be avoided by using 
protons instead of photons for a tumor positioned between the two dashed lines. The black, blue and red Bragg peaks 
represent 3 different  energy spreads with the same mean energy. The green dot is the dose at the distal  80% peak which 
corresponds to the point with the same depth regardless of the energy spread (adapted from [39]).
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The Bragg peak shape is also consequence of the energy spread and the range straggling. 
Energy spread is a characteristic of any clinical proton beam since its technically impossible to create 
a mono-energetic beam. A clinical proton beam actually consists of a small spectrum of energies with 
a certain mean energy. Since the energy of the proton beam is the property that defines the depth, this 
energy spread causes then a difference on the depth of which the protons stop. Additionally, for each 
of this small spectrum of energies there is a range straggling. This concept means that  even in a mono-
energetic beam the protons do not stop at  the same depth. In fact the energy loss, which is a process 
caused by a large but finite number of interactions, has inevitably inherent a statistical fluctuation. [3]. 
These interactions together define the width of the Bragg peak and the slope of the steep fall of region. 
The proton range is then quantitatively defined taking into account these properties of the Bragg 
peak. Depth dose measurements show that if one increase the energy spread of a proton beam with a 
certain mean energy, the distal 80% point  of the peak remains the same (figure 2). The depth at  this 
correspondent point is then considered the range of a proton beam [3].
2.2. Proton therapy techniques
A unmodified proton beam - often named as pencil beam - that  is extracted and transported from 
an accelerator, has dimensions on the order of millimeters and a narrow energy spectrum, as referred 
above. However the dimensions of the clinical target  are in general larger than the proton beam and 
with different shapes. Therefore it is necessary to spread out the beam in three dimensions in order to 
cover the entire volume of the target with the required dose.  
There are different  deliver techniques in proton therapy created to manipulate the proton beam 
and are divided into two modes: passive scattering and active scanning. The first  mode is currently the 
most mature and used worldwide and apply mechanical instruments to spread out and create a broad 
beam suitable for therapy. The second one comprises the use of several techniques in order to handle 
the position of a single pencil beam across all the volume of the target.
At PSI passive scanning is only used in the horizontal beam line at  OPTIS 2. On the other hand 
both Gantry 1 and Gantry 2 perform active scanning, despite using different techniques. 
2.2.1. Passive scattering: the spread-out Bragg peak
Passive scattering uses scattering and range shifters materials to scatter the beam laterally and in 
depth, respectively (figure 3a). These components are placed in the nozzle, the head of the gantry. 
There are actually different approaches to broaden the beam using different  scatter foils. Generally a 
first  flat  scatterer is used to scatter the beam uniformly to a second scatterer with variable thickness, 
which scatters the beam more in the center than close to the edges. This composition flattens out the 
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lateral profile of the initial beam, which is a Gaussian with a spread of about 1 centimeter [3, 20, 23]. 
In order to conform the beam laterally is used an aperture which serves as well as collimator. The 
shape of the aperture is defined according to the shape of the target, with margins made usually of 
brass that  collimates the beam, preventing the healthy tissue next to the target of receiving dose. This 
component should be placed close to the patient so then the penumbra could be minimized [3, 20].
 Along with the lateral conformation it  is also necessary a depth conformation of dose. As 
explained before the depth dose curve of a pencil beam is a Bragg peak, characterized by a high 
variability of dose deposition in depth. To obtain thus a homogenous dose distribution over the target 
volume it was found out that a superposition of many Bragg peaks with a specific energy and weight 
would fulfill this goal. This homogenous extension in depth is named spread-out  Bragg peak (SOBP) 
(figure 2). To practically achieve that  it is used a range modulator device such as a range modulation 
wheel or a ridge filter. The first  one is the most  commonly used and consists of a wheel with steps of 
varying thickness which is irradiated while the wheel rotates. The thickness of each step determines 
the range shift  of the Bragg peak and the angular width determines the weight of that Bragg peak [3]. 
Compensators are as well used. They define the shape of the distal edge of the proton beam in order to 
make it  coincide with the distal surface of the target. This is accomplished adding more material to the 
compensator in the beam direction, where the the depth is small, and less material where larger beam 
penetration is desired [3, 20].
a) b)
Figure 3: a) Representation of a standard passive scattering system. First a range modulator system (range shifter or a modulation wheel), 
two scatterer foils (a flat scatterer and second scatterer with variable thickness), a collimator (aperture) and a compensator. Is it visible 
that the SOBP has always the same width along the beam direction, delivering then the prescribed dose also to the healthy tissue proximal 
to the target. Below in the same image is represented the evolution of the lateral beam profile along the beam path. b) Representation of a 
standard active scanning system. A dynamic device which allows the definition of the proton energy (range shifter or a degrader, for 
instance) and scanning magnets which allow the dynamic change of the beam position. Below the evolution of the lateral beam profile is 
also shown (adapted from [23]).
2.2.2. Active scanning
Active scanning is a method where a narrow proton beam is applied to scan the target  both 
laterally and in depth. This can be applied by either magnetic or mechanical modes, or by the 
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combination of the two, and requires a sophisticated control system technology in order to perform a 
secure and accurate treatment (figure 3b) [20]. Active scanning nowadays is mostly performed through 
the spot  scanning technique, where the dose is delivered in small steps. Specifically, a pre-determined 
dose is delivered to a certain spot, then the beam is switched off, the magnetic setting are changed to 
target  other spot, the dose is delivered to this new spot position, and so forth. Raster scanning is as 
well used, mainly for heavy ions, and is similar with the spot scanning technique, but  the beam is not 
switched off. It is applied instead a continuous scanning of the target [3]. As well as passive scanning, 
active scanning techniques differ between facilities, depending on the specification of the research 
program or depending on the equipment  supplier. Although, to perform active scanning the main 
components are similar.
Protons are charged particles which, when subjected to a magnetic field, are deflected. This 
property is the basis to use scanning magnets (sweeper magnets) to control the lateral (transversal and 
longitudinal) position of the beam, instead of using a scatterer system to broaden the beam [24]. 
Typically the beam is scanned in a zigzag pattern in the plane perpendicular to the beam direction, 
starting in the deepest layer. To move the beam along its axis to another layer and change the range of 
the proton beam, it  is necessary to change its energy. This is done through the same method used in 
passive scattering, using a range modulation wheel or a ridge filter. 
Active scanning has some advantages over the passive scattering method. There is no need of 
scatterers and patient specific hardware in the beam way, which are made of materials with large cross 
section for neutron production such as the aperture, placed moreover close to the patient. Additionally 
these components are responsible for a loss of around 50% of protons, making active scanning much 
more efficient. The dose conformity obtained using active scanning is better, since it can create any 
physical possible dose distribution [20]. However, the majority of facilities worldwide still uses 
passive scattering since it is a robustness technique; the nozzle components just need to be in the 
correct path in order to obtain the correct  dose, whilst  with scanning it  is necessary a sophisticated 
beam control and feedback systems [3].
2.3. Proton dose distributions
As explained, with passive scattering the target can be fully covered using the SOBP 
characteristics; allowing a dose distribution similar with the one obtained with conventional 
radiotherapy. One of the main limitations of the SOBP technique is its fixed length. The range 
modulation system defines the width of the SOBP along the beam direction, which is invariable across 
the field width, and can not be changed during a treatment field unless it  would be possible to change 
the range modulation system. Since the target  volume has a variable thickness along the beam 
direction, there are then some proximal healthy tissue irradiated with the full dose (figure 3a). In spite 
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of being possible to create a SOBP with active scanning, the goal is to create a variable effective depth 
dose curve across the width of the field in order to achieve a better dose conformation and spare the 
healthy tissue. 
2.3.1. SFUD and IMPT
At PSI two active scanning delivery techniques are implemented in both gantries and can be 
used for clinical treatments. Single field uniform dose (SFUD) is a dose delivery technique equivalent 
to the SOBP dose distribution obtained with passive scattering. However, only the Bragg peaks within 
the target  volume are delivered and the weight  (fluency) of each individual Bragg peak is optimized 
and modulated [24]. This optimization is performed per field individually in order to create a more or 
less homogeneous dose distribution (within ±10% of the prescription dose). Unless for specific 
treatments such as ocular melanomas, the SFUD treatments are performed commonly as a contribution 
of several optimized fields in order to improve the homogeneity of the dose distribution and the 
robustness of the treatment. In the context  of the project thesis, all the dosimetric plans created were 
calculated and performed with the SFUD technique [3].
Active scanning actually stands out by the possibility of delivering intensity modulated proton 
therapy (IMPT), the proton therapy equivalent  to IMRT. The major and relevant difference between 
IMPT  and SFUD is the optimization process. Rather than optimizing each individual field, the 
optimization process of IMPT takes into account all the fields used in the dosimetric plan. The fluency 
of all dosimetric plan Bragg peaks selected within the target volume are optimized simultaneously, 
regardless of the field to which they belong. Therefore, the homogeneity of the dosimetric plan is just 
achieved as the result  of the sum of all individual fields since the homogeneity per field is not  a 
required parameter. IMPT increases the flexibility of the dosimetric planning and consequently 
improves the dose conformity to the target, minimizing the dose to the healthy tissue [3, 24]. 
Specifically, for instance, the weight of pencil beams passing through some critical organ at  risk 
(OAR) could be reduced and compensated by the pencil beams of other fields. The major drawback of 
IMPT  is that the plan robustness is compromised since the single field distribution are extremely 
complex and irregular [3].
2.4. Proton therapy at PSI - CPT facility
Proton therapy is a modality of radiotherapy which requires complex, large size equipments 
inside a large facility. Nowadays a proton facility is divided into three main parts: an accelerator, a 
beam transport  system and a treatment  delivery system. Each one of the equipments are configured 
and selected according to the delivery techniques used and the patient  tumor location. Usually, for an 
efficient use of the beam, one accelerator is the source for several treatment delivery systems [20]. The 
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PSI CPT  facility is not  an exception: it consists of an accelerator serving two treatment rooms with a 
gantry each and a third room with a horizontal beam line (figure 4) [7].
a) b)
Figure 4: a) Layout of the CPT facility. The COMET accelerator serves 4 treatment rooms: Gantry 1 and Gantry 2 treatment rooms; 
Optis 2 treatment room with an horizontal beam line and Gantry 3 treatment room, which is under construction to date. b) Image of the 
Gantry 2 treatment room where were performed the experimental measurements (adapted from [7]).
There are two specialized accelerators used in proton therapy: the synchrotron and the 
cyclotron. The synchrotrons main advantage is that they allow the extraction of protons when it 
reaches the desire energy, but they have larger dimensions than the cyclotrons. These latter ones are 
smaller but  they produce protons with a fixed energy. The variation of the energy must  be then done 
downstream on the beam line using fast  degraders, i.e., inserting a variable amount of material in the 
beam line [3, 20]. At  CPT  it was installed a more compact superconducting cyclotron which 
accelerates protons to a fixed energy of 250 MeV. This accelerator type was chosen since the way of 
energy selection associated to it allows the development of more performing scanning techniques such 
as specific techniques for moving targets. At Gantry 2 for instance, along with a range shifter a 
degrader was installed upstream in the beam line (figure 5). The energy changes with a high rate, in 
small steps very quickly (takes around 100-150 ms), whilst  in a synchrotron it is necessary to wait for 
the next  pulse of acceleration [25]. On the other hand, this method of reducing the energy also 
deteriorates the quality of beam and brings some safety issues that must be corrected. [25].
Proton beams reach the treatment delivery system guided and focused by magnetic structures in 
the beam line. Rotational gantries are the most  used treatment delivery system in proton centers, 
however, as referred above, for special tumors like ocular melanomas a horizontal beam line is 
preferred. Proton therapy gantries were created essentially to allow the beam to be directed towards 
the patient from any direction of the vertical plan of rotation. In Gantry 2 nozzle for instance, two 
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sweeper magnets control the lateral position of the pencil beam, which then is deflected by a 90ª 
bending magnet. Together with a couch which can have six degrees of freedom it is possible to 
achieve many beam directions [26]. 
Another important  characteristic of gantries is that its spatial positions and the position of the 
patient  must  be extremely reproducible because the tumors are always located close to the healthy 
tissue. Additionally, a high position stability and shape invariance of the beam must be provided at all 
gantry rotation angles in order to achieve a high beam-pointing accuracy. Gantries are actually a 
technically complex structures since they are equipments with a huge size and a weight  of about 100 
tons that must be controlled with a sub-millimeter mechanical precision [20, 25]. 
Figure 5: Gantry 2 active scanning representation. On Gantry 2 scanning is performed based on two sweeper magnets (U and T) and an 
energy degrader system (S). The degrader is situated just after the cyclotron and not on the gantry itself. To change the horizontal 
direction of the beam to a vertical direction, a 90º bending magnet is used (adapted from [26]).
All of these techniques are controlled by the specifications implemented on the treatment 
planning systems (TPS). These specifications are translated afterwards to the equipment  in order to 
perform the treatment  according the dosimetric plans created. PSI has created its own TPS, named 
PSIplan, which is constantly under development. The TPS has currently different  versions according 
either the clinical or research interest  and the proton therapy gantry used. Like the majority of proton 
TPSs worldwide, PSIplan uses analytical algorithms as the core basis for dose calculations. 
Concerning the clinical data needed for the calculations, PSIplan uses binary files as input. For 
instance the DICOM planning CT obtained from the CT  scanner is converted to a specific file format 
defined at  CPT, which is a binary file with the extension CTCT, full of integers representing the scaled 
Hounsfield units. The HU start  at  -1000, however, within CTCT file the scaled HU are used, which are 
shifted +1000 values (explained in 2.6 sub-chapter).
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PSIplan is able to calculate different dose distributions according the clinical specifications. 
These dose distributions may be calculated using the SFUD technique or IMPT. Additionally, it  has 
integrated some optimization tools such as the robustness plan tool (sub-chapter 3.2.1).
2.5. Range uncertainties
One important characteristic in proton therapy that should be pointed out is that the clinical 
evaluation of the calculated dosimetric plan is always done through the data obtained from a software. 
In fact, even with the more sophisticated calculation algorithms, this is not  only more, at  the best, than 
an approximation of the dose that  is in truly delivered to the patient as well as of the position where 
this dose is deposited. This is a reality not  only for proton therapy but  also for conventional 
radiotherapy. Therefore, uncertainties along the treatment process are inevitable [24]. Some of these 
uncertainties such as the patient position, are random in nature and are thus mitigated along the 
fractionated treatment, however, systematic uncertainties are part  of the treatment process and can be 
potentially more critical.  
As introduced, the exploitation of the proton beam steep fall-off and consequent  finite range is 
the main advantage of proton therapy, allowing great  conformal dose distributions. Nevertheless, the 
location of the Bragg-peak is not  always well predicted, specially for complex patient  geometry, and 
small variations in the proton beam range can potentially cause substantial over-dosage of the healthy 
tissue or an under-dosage of the target volume (the dose delivered should be within 5% of the dose 
prescribed). The causes of this uncertainty have been therefore highly investigated in order to be 
minimized since a reliability on an accurate determined depth is fundamental [3, 24]. Range 
uncertainties arise from four different sources: organ motion, setup and anatomical variations, dose 
calculation approximations and biological considerations [4]. 
Firstly, there are uncertainties in the range, random in nature and independent  of the dose 
calculations. Specifically, they are caused by variations of the patient position and beam 
reproducibility. The latter one has generally a small magnitude (influence of ±0.2 mm in the range), 
but the patient setup has already a relevant influence of ±0.7 mm in the range, which can be increased 
in the presence of high heterogeneities [4]. Again, due to their random nature they tend to blur out 
under the typical fractionated treatments. The commissioning process also introduces an uncertainty 
(±0.3 mm), which is systematic, and patient anatomy changes, despite being generally random, can be 
systematic (for instance tumor shrinkage) and have gradual but severe effects in the range during the 
treatment process [2, 4]. 
Still independent of the dose calculations are the range uncertainties caused by biological 
effects. Specifically uncertainties due to variations in RBE. The RBE value is not constant, depends on 
several physical and biological properties, but  in proton therapy it is used an average invariable value, 
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as referred in the 2.1.2 sub-chapter. This approximation is responsible for an uncertainty in the range 
of around 0.8% [3, 4].
There are also range uncertainties due to MCS algorithm limitations. The extent of these 
uncertainties are dependent on the TPS calculation method, i.e., whether it  is based on Monte Carlo 
simulations or in analytical algorithms. At PSI, as well as in most  proton therapy facilities, analytical 
algorithms are implemented within the TPS mainly because they are extremely fast compared with the 
actual Monte Carlo TPS systems. Concerning analytical algorithms, they generally project  the range 
based on water equivalent  depth and are less sensitive to abrupt density variations such as bone-tissue 
interfaces. The range degradation effect  is then not  well modeled by these algorithms resulting in a 
range uncertainty of around 1.5 mm (-0.7%). In fact these effects can be much more negative. In 
complex structures with high heterogeneities, such as the skull, the range can be reduced by up to 8 
mm [4].
Finally, the treatment planning systems (TPS), as in conventional radiotherapy, use CT  images 
as a basis for treatment  planning. Range calculations are then dependent  on the limitations of CT 
image acquisitions such as image noise or reconstruction artifacts. This uncertainty is around ±0.5% of 
the range for modern CT  scanners [4]. Additionally, in proton therapy the CT Hounsfield units must be 
converted to relative proton stopping power values (sub-chapter 2.5). Even though sophisticated 
methods and algorithms have been developed to do this conversion, there are still relevant 
approximations that add a considerable uncertainty in the calculation of the range [2]. First, the 
uncertainty in the range due to the stoichiometric conversion itself (the one used for the CT  calibration 
at  PSI) was estimated as ∼0.5%. Second and more important, there are a relevant uncertainty in the 
calculation of the stopping power values due to variations of the mean excitation energy (I-value). 
These variations are responsible for an uncertainty in the range calculation of ∼1.5% for tissues [4]. 
Taking into account  all of these CT  parameters, the range uncertainties caused by a well calibrated 
good quality CT are in the order of ±3% [2].
2.6. CT HU to relative stopping power
Treatment  planning systems, which take into account  the tissue inhomogeneities, require 
information about the anatomical structures in order to be able to calculate dosimetric plans. Since the 
advent of proton therapy, this anatomical data has came indirectly from CT imaging. CT imaging 
provides a 3D spatial map of voxels representing the patient’s anatomy together with a CT number 
expressed in Hounsfield unit (HU). The HUs represent  the relative tissue attenuation of x-rays in water 
and is given by [27]:
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They start  at -1000 (the HU value for air). The value 0 is the HU of water and higher values 
correspond to materials with photon attenuations greater than the attenuation for water. 
The properties of the physical interaction of protons with matter define the analytical algorithms 
and the physical parameters required for the calculations within the TPS. Concerning proton therapy, 
the simulation of the interaction of protons with the matter, necessary for the TPS calculations, uses 
the relative stopping power values of tissues to water, which must  be converted from the HU of the 
CT image.
Figure 6: Calibration curve used at PSI obtained under the stoichiometric method [28]. Here are used the scaled HU. The graphic was 
obtained through the manipulation of the CBSP binary file integrated within TPS, which represents the relative stopping power values to 
water.
At PSI this conversion is made through a calibration curve determined at time of CT 
commissioning, which was obtained under the stoichiometric calibration method proposed by U. 
Schneider et  al [28] and is implemented in PSI treatment planning system (PSIplan) (figure 6). This 
calibration curve relates the scaled HU values to a specific relative stopping power value. The scaled 
HU are shifted +1000 HU values, being thus the HU value of air converted to 0 whilst the HU of water 
to 1000. In this conversion curve the scaled HU higher than 4000 are converted to the relative 
stopping power of titanium (figure 6).
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3. Materials and Methods  
In this chapter it is discussed the procedures created to accomplish the goal proposed and all the 
materials used during the project, specially the description of the detectors. To preform clinical 
treatments as well as experimental measurements with a proton therapy gantry, an extensive 
planification and dosimetric planning is required. 
The project  can be divided into two sections: the experimental procedure and the analysis 
procedure (figure 7). The first  one corresponds to the CT HU changes, the dosimetric planification of 
the different scenarios, plan submission and finally the correspondent experimental measurements 
with the different  detectors. The analysis procedure is the creation of new dosimetric plans along with 
its submission to the PSIplan robustness tool in order to analyze and compare them with all the 
measurements scenarios.
3.1. Experimental procedure
In order to be able to measure dose on the surface of a phantom “skin”, one can simple create a 
dosimetric plan, use it as input for the gantry and place the dosimeters on the desired place. This 
procedure however, might  not be enough to actually allow the dosimeter detection of a significant 
amount of dose that can be used to compare with the dose predicted by the TPS. Due to this reason the 
overshooting scenarios were created. Additionally, they also lead the evaluation of the effect  caused by 
+3% range-error, simulating the uncertainty value used at PSI. 
3.1.1. Overshooting scenarios development
To experimentally evaluate the effect of range uncertainties in a dose distribution, using the 
EIVD method, they must be deliberately created in order to create an experimental overshooting
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Figure 7: Diagram summarizing the work method procedure. The green boxes correspond to the method 1 while the blue boxes to the 
method 2.
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scenario. To perform that, the proton range should be indirectly controlled and increased. Actually, 
several methods could be applied simply because there are multiple sources of range uncertainties, 
however, as referred in the chapter 2.5, CT HU conversion to relative stopping power  is one of the 
main causes of uncertainties. Therefore, it was chosen to be used as the simulation tool to indirectly 
increase the range. 
At CPT this conversion is done through the stoichiometric calibration curve which is inserted 
within TPS by a binary file [28]. The values within the CT binary file (CTCT  file), representing theHU 
of the planning CT, are the data necessary to calculate the relative stopping power, which in turn are 
the input data for the dose calculation algorithms. Changing the CTCT file HU values changes, 
perforce, the relative stopping power used for each tissue. Specifically, changing the HU of a CT for 
instance by +3% will cause the increase of the relative stopping power according the calibration curve 
implemented within TPS (figure 8). This changes were then performed in the nominal CT  and these 
modified CTs were used for TPS dosimetric calculations in order to create the dosimetric plan required 
to experimentally simulate an effect  of the range uncertainties, an overshooting scenario.
Figure 8: Calibration curve used at PSI obtained under the stoichiometric method (blue) [28]. The red calibration curve corresponds to 
the values of the relative stopping power due to a change of +3% in each HU value.
 As a matter of clarification, despite the algorithms characteristics implemented, this 
overshooting scenario is actually predicted and easily explained. Physically, to achieve the same beam 
range in two materials with different  stopping power values it  is necessary for the material with higher 
values of stopping power, higher values of beam energy, maintaining the remaining beam 
characteristics unchanged. Therefore, in dosimetric plan calculations, when all the stopping power 
values calculated from the CT  image are respectively higher than the nominal values, which is the 
case, the resultant  field energy increase in order to cover the target according the same prescription 
and constrains. At  the time of experimental measurements, this modified beam interacts with the 
phantom, which as the nominal stopping power values, causing the desired overshooting scenario. 
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In the context of the project the changes were set to be 3% and 10% of the CTCT nominal HU 
values. These changes imply a considerable change in the relative stopping power values and 
consequently in the experimental dose distribution of the fields, which will be out  of the phantom, and 
significantly  measurable by the dosimeters.
3.1.2. Dosimetric plans
In order to perform the required measurements several dosimetric plans were created using 
PSIplan for Gantry 2. The dosimetric plans were made using a CT  image taken from a head phantom. 
Three CTCT files were used each one with different HU values:
-  “Nominal scenario”: The nominal CT image, corresponding to the default CTCT file of the 
phantom.
-  “3% overshooting scenario”: A CT image with +3% of each nominal CT  image value. The 
nominal CTCT  file was read with Matlab®, modified and then rewritten. The 3% corresponds to the 
error margin adopted for proton range.
 “10% overshooting scenario”: A CT image with +10% of each nominal CT image value. As 
well as for the latter CT image, the nominal CTCT file was read using Matlab®, modified and then 
rewritten. The reason for a scenario with this order of percentage is explained on the sub-chapter 3.1.4
On the planning CT two targets, corresponding to the tumor area and two regions representing 
the organs at risk, were simulated. These same target  and OAR configuration was used during the 
entire set of experiments.
Additionally two different  fields were chosen to perform the dosimetric plans according the 
configuration of the experiments:
-  A clinical field with 110 degrees of gantry rotation and 180 degrees of couch rotation.2
-  A experimental field with 90 degrees of gantry rotation and 180 degrees of couch rotation. 
The choice of this field is related with the positioning issues of the dosimeters used in the 
experiment.
The following table sums up the dosimetric plans created for the experimental measurements 
with the dosimeters:
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2 Other clinical fields not presented in this thesis were created, however, the latter one was evaluated as the best for the purposes of the 
experimental measurements planned
Scenarios Field
1 nominal scenario
110º gantry, 180º couch 
2 3% overshooting scenario
3 nominal scenario
90º gantry, 180º couch4 3% overshooting scenario
5 10% overshooting scenario
Table 1: Summary of the 5 dosimetric plans created with the PSIplan for the experimental measurements
 For each one of the dosimetric plans the respective steering files were created and submitted, in 
order to be able to run the experimental treatment at Gantry 2.
3.1.3. Method 1 - Detector on the surface of the skin
The first  measurements were performed with the most direct  approach, placing the detectors on 
the surface of the phantom in different points. For these first  measurements it  was used both the TLDs 
and the Semiflex IC. The TLDs have good physical characteristics for the EIVD approach (portability 
and small size) and the IC was used as reference dosimeter. According with the characteristics of this 
method and the dosimeters intended to be used, 2 scenarios were evaluated:
- Nominal scenario, planned with the nominal CT;
- 3% overshooting scenario, planned with the CT with +3% of the nominal HU.
As described in the 3.1.2 section, the clinical field (110 degrees of gantry rotation and 180 
degrees of couch rotation), which was found to be a suitable field for the measurements, was selected 
for these set  of experiments. The dose prescribed according to the field was 0.5 Gy, corresponding 
to0.45 Gy(RBE). During the the experimental measurements the dosimeters were placed on 4
Figure 9: Image of the TLD positioning on the skin of the phantom preformed with the help of the positioning lasers system.
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different  points that  were evaluated during the analysis procedure (sub-chapter 3.2.2). This positioning 
was made with the support of the positioning lasers system existing in the treatment room (figure 9). 
Concerning the IC, the measurements were performed 3 times and then averaged. TLDs 
measurements however, were not reproduced since TLDs can not be used again after an irradiation. 
They must be first subjected to a extensive readout process and then erased in order to be used again.
3.1.4. Method 2 - 2D array approach
A second method using the 2D array detector as reference was planed in order to overcome 
essentially the position errors inherent  to the detector positioning method, which become more evident 
after the evaluation of the method 1 results. The 2D array has the ability to measure the dose in a 
plane, therefore it  is possible to evaluate the dose not  only in a specific point but also in the 729 ICs, 
leading to the possibility of creating a 2D map of dose. Additionally to the 2D array, 4 other detectors 
were also used: 2 ICs (Semiflex and Advanced Markus), the diamond detector and the TLD. 
For this method three different scenarios were created:
- Nominal scenario, planned with the nominal CT;
- 3% overshooting scenario, planned with the CT with +3% of the nominal HU;
- 10% overshooting scenario, planned with the CT with +10% of the nominal HU.
As described in 2.3.4, the window thickness of the 2D array, 9.3 mm of WET, should be taken 
into account. Since the measurements were made in the distal fall-off region of the Bragg-peak, this 
entrance window, made of PMMA, is thick enough to do a significative modification on the beam, 
stopping a high percentage of protons so that the ICs under it  would not detect  any dose. Thereby, in 
order to make sure the range would be increased and it  would be possible to detect a significative 
amount of dose, the 10% overshooting scenario was created. 
Due to the position limitation of the 2D array, instead of the clinical field, a experimental field 
(90 degrees of gantry rotation and 180 degrees of couch rotation) was used. The dose prescribed to the 
target  as influence of the field was 1 Gy or 0.91 Gy(RBE). The 2D array was set up perpendicular to 
the beam, over its own lateral face, and the point dosimeters were placed over it  surface when the 
measurements took place (figure 10). 
Unlike method 1, where the points were chosen analyzing the plans created in the analysis 
procedure, the detectors were placed in two different places (figure 11) chosen through the analysis of 
the 2D array measurements results:
- Point E: Over  the central IC of the 2D array (array coordinates: row (R)=14, column (C)=14);
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- Point F: Over the 2D array IC where it  was found out to be the point with the highest dose 
(array coordinates: R=12,C=11).
In this method all the measurements were reproduced 3 times for all the dosimeters, except  for 
the TLD, due to the same reason explained in the sub-chapter 3.1.3.
a) b) c)
Figure 10: a) Image of the general set up of the experiments. The 2D array was placed behind the gantry point of view. b) procedure 
concerning the placement of the TLDs. They were placed over the 2D array in the 2 points of dose evaluation. c) representation of the 
diamond detector positioning method in the central point (R=14, C=14). The ICs were positioned using the same method.
a) c)
E
b)
F
Figure 11: Representation of the detector position in the nominal scenario. a) for the 2D array the dose in the TPS was evaluated 9.3 
mm WET inside the entrance window (grey). The CT coordinate in x direction is X=171. b) For the point dosimeters, in the TPS, the 
dose was evaluated on the surface of the entrance window (grey). The CT coordinate in the x direction is X=166. c) graphical 
representation of the 2D array. The red squares correspond to the position of the 2 points were the dose was evaluated.
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3.1.5. Dosimeters
Several dosimeters with different characteristics were tested in the project. Four point 
dosimeters: thermoluminescent dosimeters (TLD), a diamond detector, a standard ionization chamber 
(IC) and a plane parallel ICs. Additionally, the feasibility of a 2D array detector was also tested.
3.1.5.1. Thermoluminescent dosimeter (TLD)
Thermoluminescent dosimeters are commercial available in various forms (e.g. powder, rods, 
chips and ribbons) and are made of different materials.TLDs operate based on the properties of some 
materials which, upon absorption of radiation retain part of that energy in metastable states. 
Specifically, TLDs have a storage trap structure, made of impurities and imperfections, that depends 
on the crystal used (most common being LiF:Mg), placed between the valence and conduction band. 
When the crystal is exposed to ionizing radiation the electrons are promoted to the conduction 
band,leaving a free hole in the valence band. Then, they migrate along the crystal until they lose 
energy and become trapped in electron traps [29]. Later on, when reading the TLD, following the 
excitation by heat, the energy stored in the traps is released in form of light, which can be read by a 
photomultiplier tube. The amount of luminescence is thus proportional to the absorbed dose received 
from the ionizing radiation[6]. 
For the experimental measurements TLD-100 (LiF:Mg,Ti) rod models (Harshaw Chemical 
Company, Solon, OH) with 1 mm in diameter and 6 mm in length (Figure 12) were used. The readout 
of the dosimeters were carried out using a TLD annealing oven (PTW, Freiburg, Germany) and a TLD 
reader (Teledyne Brown Engineering). 
Figure 12: TLD-100 used in the experimental measurements.
3.1.5.2. Ionization Chambers
ICs can be found in different sizes and shapes depending on the purpose. The most  widely used 
are cylindrical ICs (thimble IC) and plane parallel ICs, both used in the project. The first ones consist 
of a gas filled cylindrical cavity surrounded by a conductive outer wall with a collecting electrode in 
the central axis. The ionizing radiation interacts with the gas creating ion pairs which are then 
28
collected, creating a current that can be read by an electrometer. Parallel plane ICs consist  of two 
conductive walls disposed parallel to each other. The entrance wall is the polarizing electrode while 
the back wall is the collecting electrode, which is a thin conducting layer of graphite disposed on a 
non-conducting material [29, 30].
Within the cylindrical IC category it was chosen the PTW Semiflex with a sensitive volume of 
0.125 cm3. It  has a diameter of 5.5 mm and 6.5 mm length (figure 13a). The plane parallel IC used was 
the Advanced Markus, from PTW as well, with a sensitive volume of 0.02 cm3, a diameter of 5 mm 
and thickness of 1 mm (figure 13b). Both ICs have an entrance windows of 1 mm and 1.06 mm water 
equivalent thickness (WET), respectively, calculated in photon beams (figure 13c and 13d) [30].
a) b)
c) d)
Figure 13: a) PTW Semiflex IC and it schematic representation. b) PTW Advanced Markus IC and the respective schematic 
representation. In both schematic representations, c) and d), the red area corresponds to the sensitive volume while the blue are to the 
capsule. The water equivalent thickness of both capsules is around 1 mm (adapted from [30]).
3.1.5.3. Synthetic Single Crystal Diamond Detector (SCDD)
Diamond detectors hold a synthetic single crystal diamond structure which is a material ideal to 
build small volume high-resolution solid state detectors. Due to the diamond properties such as tissue 
equivalence, requirement of almost no energy correction, very good energy response and negligible 
directional dependence, they have been considered promising for relative dosimeter with proton beams 
and can be used in high dose gradient regions [29, 31]. 
The SCDD used in the project  was a test version from PTW built  in collaboration with the Tor 
Vergara University in Rome (figure 14a). The detector structure consists basically of a deposition of 
three layers of a synthetic single crystal diamond, with different characteristics, followed by a 
aluminum layer in order to form a diode. This detector operates with no external bias voltage since 
there is a built-in potential at  the diamond interface with the metal [31]. Specifically, when the incident 
radiation interacts with the diamond, positive and negative charge carriers are sorted out by the field of 
the diode. These charges produce a current which can be measured afterwards by an electrometer [32].
The diamond volume is 3 × 3 × 0.3 mm3 but  the sensitive volume corresponds to the junction 
region extended through the thickness of the upper diamond layer below the whole circular metal 
contact  (figure 14b). This sensitive volume is 0.004 mm3. The housing of the detector is made of 
polymethyl methacrylate (PMMA) with 7 mm diameter and 45.5 mm length. The WET of the entrance 
window is 1.1 mm calculated in photon beams [31, 32].
a) b)
Figure 14: a) SCDD test unit of PTW. b) Schematic representations with the size of each part of the diamond detector. The red area 
(zoomed in) corresponds to the sensitive volume while the blue are to the capsule. The WET of the capsule is around 1.1 mm (adapted 
from [30, 32]).
3.1.5.4. 2D detector array
The 2D detector array is a two dimensional device with 729 ICs arranged in a 27 by 27 matrix 
(figure 15a). They have cubic shape with 5 × 5 × 5 mm3 and are equally spaced by 1 cm centre to 
centre, covering a area of 27 × 27 cm2 (figure 15b). The sensitive volume of each IC is 125 mm3. The 
surrounding material is PMMA and the window thickness of the 2D array is 5 mm, being the reference 
point  of each IC located at the same distance below the surface. This window thickness for the 
detector used in the experiences was measured in-house, in order to find the value in proton beams, 
and corresponds to 9.3 mm of WET [33].
30
a) b) c) 
Figure 15:  a) PTW 2D array detector (adapted from [30]). b) Schematic representation of the ICs, their size and the distance between 
them. The red color represents the sensitive volume of the PTW array. c) Representation of a lateral schematic view of the PTW 2D array 
detector. The blue area represents the window thickness with a 9.3 mm WET.
The 2D array detector was used mainly because of its ability to create planar dose 
measurements of the proton beams (2D maps). This feature is able to overcome positioning errors 
inherent to the point  dosimeters placement method. On the other hand, the placement of the 2D array 
is not as flexible as it is for the point dosimeters, thus implying a set  up of a specific experimental 
dosimetric plan (sub-chapter 3.1.2 and 3.1.4). Another design drawback of this detector is it relevant 
window thickness. This window thickness, corresponding to 9.3 mm of WET, should be taken into 
account when analyzing the dose projected by the TPS (figure 15c). This thickness is big enough to 
cause an energy loss while the beam crosses it, making considerable dose changes between the dose at 
the IC depth and the dose at  the surface of the array. Consequently, the simulation of this window 
thickness must be done.
3.1.5.5. Characterization of non-standard dosimeters
Within the 5 different detectors used for the experimental measurements, the ICs (including the 
2D array) are the only dosimeters standardized by the International Atomic Energy Agency for proton 
beams [34]. For that reason they can be used as reference dosimeters. Therefore, TLDs and the 
diamond detector should be characterized relatively to the IC. 
TLDs dosimeters, each one with a calibration factor, were characterized, measuring a dose 
profile in depth and comparing it with IC. To measure the dose in depth, 20 TLDs were placed in a 
spiral shape inside a PMMA (density: 1.18g/cm3) cylinder and spaced in depth. The cylinder was then 
fitted in a PMMA cube phantom adapted for such purpose. The same measurements were done with 
the PTW Advanced Markus IC placed in a specific mechanism specially made to measure dose in 
depth. The measurements were performed in the horizontal beam in OPTIS 2 and two different depth 
dose approaches were set up: a single Bragg peak measurement, without modulation wheel and a dose 
of 1 Gy to a calibration depth of 16.65 mm; and a SOBP, with modulation wheel and a dose of 1 Gy to 
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a calibration depth of 22.80 mm. The energy of the beam was 64.26 MeV, calculated using the range 
of the beam measured with the IC software interface.
a) b)
Figure 16: a) Comparison of a single Bragg peak depth dose curve between TLDs and IC measurements. Normalization at the calibration 
depth of 16.65 mm. b) Comparison of a depth dose curve of a modulated proton beam (SOBP) between TLDs and IC measurements. 
Normalized at the calibration depth of 22.80 mm.
The results of TLDs characterization are presented in the following graphics (figure 16a and 
16b), which compares the single Bragg peak and SOBP depth dose curve of the TLDs with IC 
measurements. The data are normalized at the correspondent  calibration depth - 16.65 mm for the 
single Bragg peak and 22.80 mm for the SOBP.
The results show an agreement between both dosimeters on the first  half of the path. For the 
first  measurements, the Bragg peak depths determined from IC and TLDs were 33.45 mm and 32.89 
mm, respectively. So, the difference between both measurements is within 2%. Regarding the SOBP 
measurements the range calculated agreed within 3% (the depth of the IC measurements is 33.29 mm 
and the TLDs measurements is 32.15 mm). It  is clear in both graphics the under-response of TLDs in 
the peak and fall-off zone. TLDs and other dosimeters usually show this Bragg peak quenching 
resulting from an energy-dependent response [3].
The procedure for the characterization of the diamond detector was different  than the one used 
for the TLDs. The characterization was made in Gantry 2 using a water scanning system which allows 
to measure dose in depth. Two experimental measurements were performed using a 70 MeV beam, the 
first  with the PTW Semiflex IC attached to the water scanning system and the second using the 
diamond detector. Depth dose measurements were calculated for both dosimeters in order to compare 
the results of the diamond detector with the reference IC results and find a calibration factor for the 
diamond detector. The calibration factor calculated was 1.4795E+09 Gy/C. The results are graphically 
represented in the figure 17. They show a very good agreement  between the response of the diamond 
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detector when compared with the IC. The difference in the measured range is around a tenth of 
millimeter.
Figure 17: Depth dose curve measured with a water scanning system using the reference IC and the diamond detector. The results show a 
good agreement between both detectors.
3.1.5.6. Dosimeters global evaluation
The dosimeters referred in this chapter show different advantages and disadvantages for the 
EIVD approach. Despite that, all of them were used in order to find which one could be better applied 
in the approach. The following table summarizes a relative qualitative evaluation:
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Advantages Disadvantages
TLD
Portability;
Easy to place on the patient.
No voltage is applied
Under-response on the Bragg peak fall -off 
region;
Post-processing is necessary;
High probability of positions errors due to 
the encapsulation and the size of the 
dosimeter.
IC (Semiflex 
and Markus
Good reproducibility;
Good dose linearity;
On-line results.
Unpratical placement;
Probability of position errors;
Safety issues due to voltage;
Cables are needed.
Diamond 
detector
Good reproducibility (±0.5%) [31];
Good dose linearity [31];
On-line results;
Can be in contact with the patient because 
no voltage is applied.
Unpratical placement;
Probability of position errors;
Cables are needed.
2D array
Good reproducibility (±0.5%) [33];
Good dose linearity [33];
On-line results;
2D information.
Unpratical placement;
Simulation of the window thickness is 
necessary;
Cables are needed.
Table 2: Relative qualitative evaluation of the detectors used in the experimental measurements. The evaluation was made according the 
characterization of the dosimeters, throughout the correspondent bibliography and analysis of the experimental method during the 
experiments.
3.2. Analysis procedure
3.2.1. Robustness plan tool
The robustness plan tool is a software implemented within PSIplan with the goal of improving 
the robustness of the dosimetric plans. Specifically, this tool allows the re-calculation of the fields 
characteristics (Bragg-peak selection and optimization) assuming a general error of a certain 
percentage in the nominal HU values (in the project a percentage of +3% and +10%). Then, these 
optimized re-calculated fields are used to calculate the final dosimetric plan in the nominal CT in order 
to simulate the effect of the range uncertainties [3, 35]. 
In the context of the project this tool can be used to simulate the overshooting scenarios created 
for the experimental measurements, simulating a dosimetric plan where can be analyzed the effect of a 
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modification of 3% or 10% in the HU. Therefore, and as a matter of clarification, these simulated 
overshooting plans are indeed different from the ones created in the experimental procedure. Actually, 
these simulated overshooting dosimetric plans obtained from the robustness plan tool adopt the same 
field characteristics of the experimental overshooting plans in order to calculate a dosimetric plan in 
the nominal CT, which will naturally lead to a overshooting simulated scenario. It  is in fact  a 
simulation of what happens in the real experiments.
3.2.2. Method 1 - Detector on the surface of the skin
To analyze the dose distributions a nominal evaluation plan was created under PSIplan, with 
both the clinical field and the dose prescribed referred. The correspondent overshooting plan (3% 
overshooting plan) obtained from the robustness plan tool was calculated, in order to not  only be used 
to evaluate the dose predicted by the TPS but  also to define the 4 points where the dosimeters were 
placed for measurement  (sub-chapter 3.1.3). These points were located in a region where could be 
feasible to accomplish the goal established (figure 18). Consequently, the following points were 
selected:
a) b)
A B
c) d)
C D
Figure 18: Representation of the detector positions in the nominal scenario and dose distribution obtained using the robustness plan. a) 
Point A; 1st point in the direction of the field. CT coordinates: 158, 148, 111. b) Point B; 2nd point in the direction of the field. CT 
coordinates: 159, 121, 104. c) Point C; point with the greatest dose difference between the nominal and the overshooting plan. CT 
coordinates: 162, 130, 117. d) Point D; point with almost no dose in the nominal plan. CT coordinates: 162, 137, 107.
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- Points A and B: 2 points in the direction of the field;
- Point C: point with the greatest  dose difference between the nominal and the 3% overshooting 
plan obtained from the robustness plan tool; 
- Point D: point with almost no dose in the nominal plan.
Finally, so that  the goal could be accomplished, all the experimental measured results were 
directly compared against  the results from the nominal and overshooting plans obtained in the analysis 
procedure. This comparison was the tool to understand the extent  of the uncertainty in the range for 
each field.
3.2.3. Method 2 - 2D array approach
Similarly to method 1, the comparison of the experimental measurements with the nominal and 
overshooting plans (3% and 10% overshooting) created with the robustness plan tool was also the way 
of evaluating the effect  of the range uncertainties. However, as referred above, there are a relevant 
interference of the entrance window in the beam range and consequently in the dose measured. Thus, 
this entrance window should be taken into account before creating the plans for analysis.
3.2.3.1. Simulation of the 2D array entrance window
As referred before, it  is necessary to replicate the real effect  of the 2D array entrance window 
thickness within the calculation of the dose in the analysis procedure. To do that, since there is a direct 
relation between the stopping power values and the HU, given by the calibration curve, the entrance 
window WET  was simulated within the CT  image. This simulation can be simply made by replacing 
the default  air HU values of the original CT image (CTCT file) corresponding to the position of the 
entrance window with the water HU values obtained through the calibration curve. 
As described before, the CTCT  binary file is the converted CT image used within PSIplan, with 
an array of values corresponding to the HU of each voxel. Each CT cube used in PSIplan is a group of 
voxels formed out  of  255 slices in the x and y direction and 171 slices in the z direction (figure 19a). 
In the x and y direction the slices are spaced by 1.953 mm whilst in the z direction they are spaced by 2 
mm. Each voxel is actually a cuboid with the dimensions 1.953×1.953×2 mm3. As explained above, 
the 2D array is placed with the front face perpendicular to the beam direction, which corresponds, in 
CT coordinates, perpendicular to x (figure 19a). Thus, the thickness of the entrance window must be 
created, changing the air HU (0) of a certain number of slices in the x direction of the original CTCT, 
with the water HU (982) (figure 19). This value, 982HU, corresponds to the HU value that is 
converted to the relative stopping power of water, which is 1, according the calibration curve.
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To perform that it was calculated how many slices with 982 HU it  is necessary simulate. simply 
dividing 9.3 mm, the WET  of the entrance window, by 1.953 mm. The result  is 4.762. This value show 
that 4 slices with 982 HU should be created along with one slice with 76.2% of the relative water 
stopping power value (0.762×1). According to the calibration curve the HU value corresponding to a 
relative stopping power of 0.762 is 764 HU.
a) b)
764 HU
982 HU
982 HU
982 HU
982 HU
Figure 19: a) Matlab® simulation of the 2D array entrance window. b) representation of the 5 voxel slices of the 2D array. The 764HU 
voxel slice is represented by the first row (barely visible on figure19a) and the four 982HU voxel slices by the next 4 rows. The red and 
yellow lines represents the slices were it was measured the dose in the analysis procedure.
Finally this simulation was converted to a CTCT file by a function created in Matlab® in order 
to be implemented within TPS as a nominal CTCT  file. This file was used as input  for the robustness 
plan tool to create the overshooting plans. The dose was further analyzed in two different slices. In 
order to compare the dose with the dosimeter measurements placed on the surface of the 2D array, the 
dose was evaluated in the slice representing the 2D array face (slice between the red line in the figure 
19b. Slice x=166 figure 19a). On the other hand, to compare with the 2D map obtained directly from 
the 2D array measurements, the dose was also evaluated behind the 5 voxel slices representing the end 
of the entrance window (voxels corresponding to the slice between yellow line in the figure 19b. Slice 
171 figure 19a). 
37
38
4. Results
As described in the materials and methods chapter, to find a feasible way to perform the EIVD 
approach, two methods were implemented. On the first  method, the dosimeters were placed directly in 
the patient  and a clinical field was used for the measurements. In the second method it  was taken 
advantage of the 2D array properties in order to perform the measurements. A experimental field was 
used and dosimeters were placed on the 2D array surface. The idea is to compare the results against 
the dose predicted by the TPS. In fact, analyzing the potential extent of dose difference between the 
one planned and the one that is actually measured it  is possible to evaluate the feasibility of each 
dosimeter on the EIVD approach. This chapter gathers the results obtained from the experimental 
measurements, which were post-processed either through Matlab® or using the respective standard 
post-processing method.
4.1. Method 1 - Detectors on the surface of the skin
Two types of dosimeters were used in this method: a Semiflex IC and TLDs. They were placed 
in 4 different  points and the measurements were performed using the nominal and the 3% 
overshooting scenarios. The experimental results were compared with the TPS results obtained 
through the correspondent analysis plans. 
4.1.1. Results
The results are displayed in table 3 and figure 20 show a comparison between the dose predicted 
by the TPS for 4 superficial points evaluated (red triangle marks in figure 20) against the dose 
measured by both the IC Semiflex and the TLDs. The IC was not used neither at point B or point D.
A general analysis of the results for all points and scenarios show clearly that  the TPS 
overestimates de dose actually delivered and measured by the detectors. This overestimation, over
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TLD 
(mGy)
IC 
(mGy)
TPS
(mGy(RBE)) TLD/TPS IC/TPS TLD/IC
A
nominal 95 103 187 0.51 0.55 0.92
overshooting 3% 134 144 235 0.57 0.61 0.93
B
nominal 23 94 0.24
overshooting 3% 50 180 0.28
C
nominal 18 27 49 0.37 0.55 0.67
overshooting 3% 47 69 159 0.3 0.43 0.68
D
nominal 0 7 0,00
overshooting 3% 6 98 0.06
Table 3: Results of method 1 measurements for the 4 points where the detectors were placed, compared with the ones obtained by the 
TPS dose distribution. Additionally the ratio between dosimeters and the TPS was calculated as well as the ratio between the two 
dosimeters.
a) b)
Nominal 3% overshooting
Figure 20: Graphical comparison between TPS prediction results against TLD and IC Semiflex measurements for: a) nominal scenario; 
b) 3% overshooting scenario. The dose predicted by the TPS takes into account a RBE value of 1.1. The error bar in the TLDs results 
corresponds to a ±15% accuracy inherent to this TLD model.
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twice the value of the measurements - for TLD sometimes around three times its value - is quite 
significative. Additionally, it is verified that the dose measured by the TLD is always lower than the 
one detected by the IC Semiflex.
Analyzing in more detail point A from both nominal and 3% overshooting, the dose measured 
by the dosimeters agree (within the accuracy of the TLD). The ratio is indeed over 0.9 (table 3). 
However, the dose predicted by the TPS is around twice the real dose (ratio ∼0.55 between the 
detectors and the TPS). Regarding point  C, the agreement  between the dose measured by both 
dosimeters do not  agree within the 15% of the TLD accuracy but  still, the dose predicted is over twice 
higher than the dose measured (table 3 and figure 20). 
4.1.2. Discussion
The results obtained through this method show a considerable difference between the dose 
predicted and the dose measured, regardless of the detector used. 
Concerning the differences between the dosimeters, it is visible the TLDs read always lower 
dose than the IC. This attribute can be explained by TLDs characterization performed before the 
measurements, since it  was verified the TLDs have an under-response when measuring dose in the 
high gradient Bragg-peak fall off region (sub-chapter 3.1.5.5).
One of the influences for this big dose variation can be also explained by the dosimeter 
placement method. In order to position the detectors the lasers existent  into the room and integrated 
within the gantry coordinate system were used, however, it is not  possible to precisely place the 
dosimeters, specially the IC Semiflex, without making some random position error. The effects of this 
error is still boosted because the measurements are being made in high gradient dose regions, not  only 
in the beam direction due to the fall off region of the Bragg peak, but  also laterally to the beam: the 
heterogeneities of the patient lead often to these lateral high gradients (visible on the dose distributions 
of figure 16). These latter characteristics of the dose distributions in the exit region of the beam, 
which in fact belong to the ±3% uncertainty in the range used at  PSI, associated with the errors in the 
positioning of the detectors are actually the main reason for the disparity of dose measured between IC 
and TLD registered in point C.
4.2. Method 2 - 2D array approach
As explained in the sub-chapter 3.1.4, this method consisted in placing the 2D array 
perpendicular to the beam in order to measure a 2D map of dose and compare it with the 
correspondent dose distribution predicted by the TPS. This 2D map, obtained through a specific 
software and later processed in Matlab®, has a resolution of 27 by 27 pixels, corresponding to the 
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location of the IC on the array plan. On the other hand the dose distribution from the TPS is a 3D 
volume with the same resolution and coordinate system as the CT volume (251×251×171 voxels). So, 
a post-processing of this dose distribution is indispensable so then the experimental results could be 
compared against the TPS output. 
Together with the 2D array measurements four point  dosimeters were placed over specific 
positions: the central IC point  (point E: R=14, C=14) and the IC where it  was found out to measure the 
highest  dose value (Point F: R=12, C=11). The dosimeters used were two ICs (Semiflex and the 
advanced Markus from PTW), a diamond detector and TLDs. 
4.2.1. 2D array
4.2.1.1. Post-processing of the TPS dose distribution
To manipulate the TPS dose distribution the Matlab® was used. The 3D dose distribution 
volume, obtained after a dosimetric plan calculation on the robustness plan tool, corresponds to a 
output file (PTDT extension) with a value of dose in each voxel. As referred in 3.6.2.1, the 2D array 
dose was analyzed on a PTDT  slice corresponding to the same plan where the ICs are placed inside the 
array, after the 9.3 mm of WET. Practically, according to the CT  volume, this slice is the fifth slice in 
the x direction of the simulated 2D array (slice x = 173) (figure 21).
For each CT image that is done for treatments, there are a spatial coordinate system associated. 
In other words, the CT  coordinates of the CTCT used to calculate the dose distribution have a 
respective transformation in room coordinates. Is then possible to relate each voxel with a room 
coordinate. Taking this into account, the 2D array was positioned with the centre of the central IC 
(R=14, C=14) in a known room position (x = 23.20 cm, y = −1.11 cm and z = −130.6 cm), which was 
then translated to the CT referential (x=173, y=121, z=119) in order to directly define which voxel on 
the dose distribution plan corresponds to the centre of this central IC (figure 21, intersection of the red 
lines). As described on the sub-chapter 3.1.5.4, the sensitive volume of each 2D array IC is a cube with 
5 mm edges. However, each PTDT  voxel is a cuboid of 1.953×1.953×2 mm. This means that the 
volume of a voxel is around 20 times smaller than the IC sensitive volume. Therefore, in order to have 
a better volume approximation, it was not only taking into account  the dose on the referred voxel but 
also the dose on its adjacent voxels by simple averaging the values.
Afterwards, according to the physical measurements of the 2D array, the location of each IC 
centre referent to the centre of the central IC was calculated.  These coordinate points were then used 
to find the voxel correspondent  to the remaining ICs centers and the same averaging method was 
performed. Through this pos-processing method it  was then possible calculate which predicted dose 
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volume on the dose distribution corresponds spatially with each 2D array IC. The output of this 
Matlab® script is a 2D map similar with the one obtained through the 2D array measurements.
a) b)
Figure 21: a) Slice x=173 obtained from the PTDT file which was created through Matlab® manipulation. The intersection point of the 
two red lines corresponds to the location of the central IC of the 2D array. CT coordinates: x=173, y=121, z=119. b) Representation of the 
2D array over the dose distribution. The voxels on each square (ICs) were averaged in order to have an approximation of the dose 
measured experimentally.
4.2.1.2. Results
In this approach, along with the nominal and the 3% overshooting scenarios, a 10% 
overshooting scenario was evaluated. Concerning the 2D array measurements, results are presented as 
a 2D map of dose standing out  the 2 points where the dosimeters were placed, point E and F. The 
results are presented in the table 4, graphics in figure 22 and set of colormap images (figure 23). In 
order to better evaluate the results, the dose variation that actually is possible to be verified as a result 
of the ±3% variation of the range (uncertainty used at PSI) was also added (grey area added to figure 
22a).
Analyzing the dose distribution quantitatively the results show a similar behavior with the ones 
obtained using method 1. Focusing on the point  E and F it is verified the TPS predicts much more dose 
than the one actually delivered (figure 22). Regarding the nominal scenario, the dose measured is not 
within the dose variation that  is possible to be verified (grey area in figure 22a). Analyzing the table 4, 
the dose predicted is over 5 times higher (ratios lower than 0.2).
Regardless of the scenarios, one can compare geometrically the shape of the 2D maps of the 
experimental results from the 2D array (left column of the figure 23) with the TPS results in order to 
evaluate the characteristics of the exit beam. The shape of the dose distribution is considerably 
different. The experimental dose distribution from the 2D array has a more homogeneous dose 
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gradient radially to the beam centre, where the highest dose pixels are situated. On the other hand the 
dose distribution predicted by the TPS shows a slightly different shape, less circular, and more 
heterogeneous. However, we can assume the centre of the beam is well predicted since the maximum 
dose was measured on the same coordinate pixels.
2D array (mGy) TPS (mGy(RBE)) 2D array/ TPS 
E (R=14,C=14)
nominal 6.1 (∼0.7%) 29.0 (3.2%) 0.21
overshooting 3% 13.9 (1.5%) 80.8 (8.9%) 0.17
overshooting 10% 44.8 (4.9%) 335.8 (36.9%) 0.13
F (R=12, C=11)
nominal 27.1 (3.0%) 167.1 (18.4%) 0.16
overshooting 3% 51.2 (5.6%) 306.8 (33.7%) 0.17
overshooting 10% 112.2 (12.3%) 696.6 (76,5%) 0.16
Table 4: Results of the method 2 measurements for the 2D array both for the central IC and for the IC with coordinates (R=12, C=11). 
The percent values correspond to the percentage of dose measured relative to the dose prescribed, 910 mGy(RBE).
a) b) c)
Nominal 3% overshooting 10% overshooting
Figure 22: Graphical comparison between TPS prediction results, corrected to the entrance window WET , against the dose actually 
measured by the 2D array in 2 points: E (R=14, C=14) and F(R=12, C=11) for: a) nominal scenario; b) 3% overshooting scenario; c) 10% 
overshooting scenario. The dose predicted by the TPS takes into account a RBE value of 1.1. 
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2D array TPS 
Nominal scenarios
3% overshooting scenarios
10% overshooting scenarios
Figure 23: 2D maps resultants of the experimental measurements for all scenarios (left). 2D maps obtained from the pos-processing 
PTDT file for the 3 scenarios evaluated. The scale values of the 2D array corresponds to Gy. In the TPS the RBE is taking into account 
(Gy(RBE))
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4.2.1.3. Discussion
Despite the position errors have no influence on the uncertainty anymore, the dose predicted is 
again significantly higher. Again, the relevant character of the heterogeneities existent  within the CT 
can be a significative cause. As explained on the sub-chapter 2.5, the heterogeneities of the patient 
insert some uncertainty in the range of the beam. In fact the head phantom, being a replica of a 
patients head, shows a high heterogeneity not only along the beam path but also laterally. There is in 
fact several abrupt density changes on the CT volume: its evident  in the figure 11a several tissue-
bones interfaces and even tissue-air interface, due to the nasal cavity. These causes in fact an increase 
on the MCS uncertainties factor which in the skull can lead to a significant reduction of the beam 
range. Consequently the dose measured is lesser and the dose distribution more heterogeneous. 
In fact, it  can be verified a dose difference between the dose predicted by the TPS and the dose 
measured, as result  of the ±3% of uncertainty in the range that actually exists in all the measurements 
performed, regardless of the scenario. However, the range uncertainties itself do not  explain this whole 
dose difference, as it  is verified by the grey areas in figure 22a. The fact  that  the dose measured is not 
within the grey area, shows that  another error which is not contemplated within the causes of 
uncertainties in the range was made. Specifically, an error regarding the project procedure.
As described the position errors no longer have an effect. Additionally, the entrance window, 
which was manually simulated, is then a possible source of error caused by the WET  theoretical 
approximation method applied on its creation. In contrast, a CT image of the 2D array together with 
the head phantom would probably be a more accurate approximation, however, it would be neither 
practically or easily to perform. 
Finally, it is known that  there are still a slightly error in the calculation of the dose in air by the 
PSIplan. This error is actually corrected concerning the air gap between the nozzle and the patient but 
between the patient and the 2D array, the error still stands. This could have been a major source of the 
discrepancies between the dose measured and the dose predicted by the TPS. This not  seem to be the 
case anyway, since the dose was also calculated in a CT  where this air gap was removed but the results 
did not have a relevant improvement.
4.2.2. Point detectors over the 2D array
Point detectors were also used to reproduce the measurements in the specified points chosen to 
evaluate the dose: point E and F. Four different detectors were used and for each one the dose in each 
point  was measured 3 times. Despite the 10% overshooting had been created specially for the 2D 
array, this scenario was as well evaluated in these point  detector measurements. The results obtained 
are listed in the following table 5 and in the graphics of figure 24.
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IC Semiflex
(mGy)
IC A. Markus 
(mGy)
Diamond 
detector 
(mGy)
TLD (mGy) TPS (mGy(RBE))
E (R=14,C=14)
nominal 51.2 (5.6%) 63.1 (6.9%) 39.5 (4.3%) 49.3 (5.4%) 195.4 (21.5%)
overshooting 3% 99.2 (11%) 117.0 (12.9%) 84.0 (9.2%) - 337.0 (37%)
overshooting 10% 184 .0 (20%) 205.6 (22.6 %) 157.7 (17.3%) 190.0 (20.9%) 549.3 (60.4%)
F (R=12, C=11)
nominal 98.1 (10.8%) 111.0 (12.2%) - 115.3 (12.7%) 620.2 (68.1%)
overshooting 3% 164.6 (18.1%) 187.1 (20.6%) - - 692.9 (76.1%)
overshooting 10% 261.8 (28.8%) 296.4 (32.6%) - 290.7 (31.9%) 845.7 (92.9%)
Table 5: Results of the method 2 measurements for the dosimeters positioned over the 2D array points: the central IC and for the IC with 
coordinates (R=12, C=11). The diamond detector was only used in the central point while the TLDs were not use for the 3% overshooting 
scenario. The percent values correspond to the percentage of dose measured relative to the dose prescribed, 910 mGy(RBE). 
a) b) c)
Nominal 3% overshooting 10% overshooting
Figure 24: Graphical comparison between TPS prediction results, against the dose actually measured by 4 different detectors placed 
points: E (R=14, C=14) and F(R=12, C=11) for: a) nominal scenario; b) 3% overshooting scenario; c) 10% overshooting scenario. The 
dose predicted by the TPS takes into account a RBE value of 1.1. 
In order to be easier analyze the results, it is presented in the table 5, along with the dose 
measured by the detectors or predicted by the TPS, the dose percentage relative to the prescribed dose, 
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910 mGyRBE. Comparing just the dose measured between the dosimeters, excluding the dose 
predicted by the PSIplan, one can assume a general agreement. The percentage dose has a variation of 
∼ ±3%  of the prescribed dose between the detectors. On the other hand, the dose predicted by the TPS 
exceeds substantially the dose measured by all the dosimeters. The graphical representation of the 
results show these differences (figure 24). Regardless of the scenario, the dose detected agree in 
general, whilst the TPS dose predicted is around 3 times more than the one measured. 
On the other hand, the dose measured is not  again within the possible dose variation represented 
by the grey area bar.
4.2.2.1. Discussion
Comparing the dose measured between the dosimeters, the position errors have again a 
significant influence. They are one of the causes of the differences that  actually are noted, despite the 
good agreement  existent  relative to the dose prescribed. Regarding the diamond detector results, it was 
not placed in it default position, parallel to the beam with the front face perpendicular to it. Instead it 
was placed laterally to it. This could have influenced the results obtained, which were lower than the 
ones obtained by the ICs and TLDs.
As a matter of clarification, the TPS values were taken from the PTDT  slice corresponding to 
the position of the detectors (slice x=166) (figure 11b), without  the influence of the 2D array entrance 
window. Taking this into account, one more time it  was evident  the range uncertainties problem when 
comparing the dosimeters results with the ones predicted by TPS. Errors inherent to the procedure 
were committed since the dose measured is not inside the grey area. Although the range uncertainties 
are inherent to the TPS calculations they do not cover these big differences. 
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5. Conclusion
It  is clear among proton therapy community that  the full potential of proton therapy will only be 
exploited when it will be possible to control and monitor the range uncertainties in vivo [2]. Actually, 
it  is notorious the importance of reducing range uncertainties since a small factor that causes a certain 
uncertainty is translated in a significant  dose variation. A precise control would allow the development 
of more convenient field directions in order to exploit the steeper distal fall-off of proton beams and 
spare the healthy tissue. In fact, in vivo range dosimetry research has been growing and several 
approaches have been proposed over the last  years [2]. The idea of this thesis project arose therefore 
from this later reality and follow the well establish in vivo dosimetry methods for conventional 
radiotherapy where actually, for instance, TLDs are used for total body irradiation [6]. 
At the outset, one important  issue regarding this EIVD approach is that  it only could be used in 
superficial targets. In targets inside a patient, due to the characteristics of proton beams, the dose 
would not  be measured outside the patient even facing an expressive uncertainty in the range. That 
was thus the first limitation of the EIVD approach proposed. On the other hand, relative to other 
methods proposed, the simple clinical methodology, the on-line results and insignificant  costs 
associated, would be an important advantage.
As explained in the methods section, one nominal and two overshooting scenarios were created 
for the experiments. In fact, after the results evaluation, if only the nominal scenario had been used, 
the dose could be measured and compared with the dose predicted for the TPS. However, the 
development  of the overshooting scenarios allowed not only the simulation of the effect of +3% error 
in the range, but also the measurement of a significant amount of dose out  of the patient necessary for 
detectors detection. 
Regarding method 1, the results obtained do not allow to take further conclusion about  the 
feasibility of dosimeters for in vivo dosimetry. They show the dose predicted by the TPS is in general 
twice the value of the dose measured. It  was verified that, besides the range uncertainties associated to 
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a treatment  (in this case experimental), dosimeter positioning was as well a source of error in the 
measurements. The dosimeter positioning method used in the experiments, even using the lasers as a 
support  system, is not sufficiently precise. Since the dose was measured in the steep fall-off region of 
the dose distribution, an high gradient  region, the position should have been considerably precise so 
that the resultant  high dose differences were not registered. However, in an eventual EIVD approach, 
the positioning method precision could not be easily improved.
Contrary to the 2D array entrance window WET, the WET  of the dosimeters capsule thickness 
was not taken into account  in TPS calculations. Nevertheless, the simulation of such thickness (around 
1 mm for each dosimeter) would not bring relevant differences in the results.
This main problem was then overcome using the 2D array in method 2. On this measurements it 
was also placed 4 different  dosimeters on the surface of the 2D array. Additionally, it  was added to the 
results obtained data obtained from the TPS representing the dose variation caused by a ±3% variation 
in the proton range (represented in the grey area). This uncertainty is indeed the possible range 
variation in all treatments performed at PSI. As explained before, the dose measured by the 5 detectors 
in the nominal scenarios were out of the grey area, i.e, not within the effect  of ±3% variation in the 
range. The overshooting scenario plans, which were used to increase the dose measured in the nominal 
to significant values, did not bring better results. Therefore, no conclusions about  the feasibility of the 
detectors for the EIVD approach could have been taken. Instead, the results showed that there was an 
error inherent to the method performed.  
Some of this errors in method 2 were in fact  taken into account. As mentioned, the simulation in 
Matlab® of the WET  of the 2D array entrance window was needed. It  was verified that this simulation 
had effects in the dose predicted by the TPS, decreasing the dose in the measurement  voxels region 
when compared to the dose in the same region calculated using the original CT, without entrance 
window simulation3. In fact, when measuring experimentally, there is a decrease in the mean proton 
beam energy, and consequently in the dose measured, due to to the entrance window. Despite this dose 
decrease, the results obtained and described in the sub-chapter 4.2 did not bring relevant 
improvements. 
Another point  that should be referred is the air that  exist  between the phantom and the 2D array 
surface. In the experimental measurements, the proton beam path before interact with the 2D array, 
crosses some centimeters (∼20 cm) of air. The effect on the beam resultant  of this amount of air is 
irrelevant, since the stopping power of air compared with the water stopping power is around 8004 
times smaller for the range of proton energies used [36]. In fact, the WET  of 20 cm of air is around 
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3 Results obtained from the original CT were not described in the thesis.
4 Calculations made through the NIST (National Institute of Standards and Technology)  PSTAR database .  
0,25 mm5 [37]. However, it is known PSIplan does not calculate the dose in air properly. The TPS 
corrects this problem in the air gap between the gantry nozzle and the phantom, but  behind the 
phantom, i.e, on the air in the opposite side of the beam nozzle, after the proton beam transverse the 
phantom, this problem persists. This could be then a source for the TPS overestimation of the results 
because the 2D array was placed in this air region. In order to try to overcome this problem, other 
entrance window simulations in Matlab® were performed, however, with no results improvement 6.
Facing this results and consequent  impossibility to take conclusions on the feasibility of in vivo 
dosimetry for proton therapy 2 hypothesis can be taken:
- The measurements are being made in an undershooting scenario relative to the TPS, i.e, the 
TPS is overestimating the range due to uncertainty sources that actually bring a value of range 
uncertainty bigger than the ±3% used at PSI. However, this is not the reality. One example is the 
work of Albertini F. et al, where GafChromic films were placed inside the same phantom used in this 
project, intersecting the target, and the dose was measured through modified dosimetric plans with a 
CT modification to simulate the range errors (same method used in the project). Results show 
excellent  agreement between the calculated and the measured dose distributions [35]. Then, the 
results of the project  should not characterize or be compared with the dose actually delivered inside 
the target and specially in a clinical treatment and range uncertainties bigger than ±3% are not  the 
case.
- Since the experimental measurements agree in general within the respective ±3% uncertainty 
and the position method uncertainty, PSIplan might  be indeed overestimating the dose on the 
opposite side of the gantry nozzle relative to the patient. In fact, incorrect  dose in air calculations, 
although not overcome, are a reality. Other unknown problems that  in fact  influence the dose 
predicted in this region by the TPS should not be discarded as well. Due to this problems evidenced 
by PSIplan and with the goal to reproduce the results obtained by the TPS, a Monte Carlo treatment 
plan (TOPAS [38]) was used. This is a Monte Carlo simulation tool focused in radiation therapy 
purposes which has been in beta test phase up to date. At PSI, however, the installation of this 
software it  is not completely finished to date, therefore, the results obtained were not relevant  for the 
project. For future projects, the reproducibility of the TPS could be performed.
This results also corroborate the reason why there are no projects published about a similar 
EIVD approach, which is widely used in conventional radiotherapy. Even admitting that the sources of 
uncertainty in the range could be the only cause of range errors between the dose predicted and the one 
actually measured, this EIVD method would have to be improved concerning the dosimeters 
positioning. In fact, the steep dose fall-off region, which is the region where the dosimeters would be 
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5 Calculations made with the WET formula taken from Zhang R. et al
6 Since the results obtained with this methods were not relevant, they were not presented in the thesis
placed in such approach, forces a extremely precise positioning. A 3% range error causes for instance a 
shift  of few millimeters (∼10 mm), depending on the heterogeneities of the medium (in water the shift 
is around 8 mm for a 200 MeV proton beam7) [36]. Therefore, the uncertainty in the position of 
dosimeters would have to be a small percentage of this shift in order to obtain relevant information.
An additional note, in case of future similar projects, for the developing of a similar EIVD 
approach is related with the methodology. In this project, the CT image used was obtained from the 
phantom head. As referred, it  has a high density heterogeneities. Therefore, for instance, a CT 
representing a water phantom could have been used for the first measurements in order to understand 
not only the extent of such heterogeneities but also to better analyze the effect  of the detector 
positioning. Finally, regardless of the results obtained, a detector similar to the 2D array but with 
better spatial resolution, would be a possible solution for this EIVD approach. A dosimeter or method 
which does not overcome the inherent position errors could indeed never be used for such approach.
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7 Calculated using the PSTAR data base from NIST website
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